Logo
Home  |  Media  |  Papers & Publications  |  Mailing List  |  Comments  |  Contact Me                                                                             Bookmark This Page
Drs. Marvin Stone and Steven Treon
Dr. Marvin Stone, Chief, Baylor Sammons Cancer Center in Dallas, Texas, and recipient of the 2004 Waldenstrom's Lifetime Achievement award with Dr. Treon following a presentation on novel treatment options for WM to the cancer center's faculty and fellows in 2008.

Download BUMC Proceedings Vol 14, number 4, Oct 2001, a conversation between Dr. Stone and the editor, William C. Roberts, MD.

Please visit our main program website: Bing Center for Waldenstrom's Research. This site contains information on the latest treatment recommendations, abstracts, news and events, current and pending clinical trials and participating institutions, basic research, and publications, as well as photos and brief bios of the Bing Center staff.


Also feel free to visit our WM Workshop Website where you will find information about our upcoming conference, IWWM-9, in Amsterdam, The Netherlands.

You may also visit our WM Summit Website where you will find information about our Patient & Physician Summit meetings on WM.

Papers and Publications

Select from the list below to view or download a paper or abstract. All documents are in .PDF format, and are organized by year of publication. Clicking the hyperlink containing the reference to its corresponding publication will open a new browser window containing the document. Please refer to the Disclaimers section of this website regarding restrictions on the use of these documents.

If this message stays visible for more than 10 seconds, then the browser you are using may not work with the contents of this page. We recommend that you update to a newer browser or check to make sure that JavaScript is enabled.

 Featured Impact Articles

How I Treat Waldenstrom's MacroglobulinemiaHow I treat Waldenstrom macroglobulinemia - Steven P. Treon
Waldenström's macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal IgM secreting lymphoplasmacytic cells. MYD88 and CXCR4 WHIM-like somatic mutations are present in >90%, and 30-35% of WM patients, respectively, and impact disease presentation, treatment outcome, and/or overall survival. ...

 

Biology, Prognosis, and Therapy of Waldenström MacroglobulinemiaBiology, Prognosis, and Therapy of Waldenström Macroglobulinemia
Waldenström Macroglobulinemia (WM) is a rare B-cell lymphoma characterized by the uncontrolled accumulation of malignant lymphoplasmacytic cells, mainly in the bone marrow, and monoclonal IgM production. Despite its rarity, our understanding of the biology of this disease has improved significantly in recent years with the identification of recurrent mutations in the MYD88 and CXCR4 genes. ...

Ibrutinib in Previously Treated Waldenström’s MacroglobulinemiaIbrutinib in Previously Treated Waldenström’s Macroglobulinemia
MYD88L265P and CXCR4WHIM mutations are highly prevalent in Waldenström’s macroglobulinemia. MYD88L265P triggers tumor-cell growth through Bruton’s tyrosine kinase, a target of ibrutinib. CXCR4WHIM mutations confer in vitro resistance to ibrutinib. ...

 

Survival outcomes of secondary cancers in patients with Waldenström Macroglobulinemia: An analysis of the SEER databaseSurvival outcomes of secondary cancers in patients with Waldenström Macroglobulinemia: An analysis of the SEER database
We hypothesized that survival outcomes of WM patients who develop SM is distinct from the general population of individuals who develop those same malignancies. Using the SEER-18 data (2000-2011), we identified patients with cancers of the breast, prostate, lung, colorectum, bladder, melanoma, non-Hodgkin lymphoma (NHL) and acute leukemia, and compared their outcomes according to having antecedent WM or not. ...